The Long, Winding Road of Immunotherapy Research
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Category: Research
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
A plenary session at the AACR Annual Meeting 2024 explored how metastases adapt to—and help shape—their new environments.
At the AACR Annual Meeting 2024, researchers discussed innovative approaches to decipher the complexities of tumor ecosystems.
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
Researchers are exploring new options for kidney cancer treatments.
Researchers are examining the gut microbiome to find better ways to diagnose and manage colorectal cancer.
This Trojan horse-like treatment strategy may help neutralize undruggable cancer drivers.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.